project . 2017 - 2022 . Closed

HIVACAR

Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 731626 Call for proposal: H2020-SC1-2016-RTD
  • Funded under: H2020 | RIA Overall Budget: 6,822,300 EURFunder Contribution: 6,685,110 EUR
  • Status: Closed
  • Start Date
    01 Jan 2017
    End Date
    30 Jun 2022
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control of viral load to levels below the threshold of 50 copies/ml and maintenance of high CD4+ T-cell count after discontinuation of antiretroviral therapy) thanks to effectively targeting residual virus replication and viral reservoirs. In order to do so, the planned novel strategy is to successfully combine immune-based therapies, including therapeutic vaccines and broadly neutralizing antibodies with latency reversing agents, in a proof-of-concept phase IIa clinical trial. HIVACAR project will lead to a reduction of the actual c...
Description
The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control of viral load to levels below the threshold of 50 copies/ml and maintenance of high CD4+ T-cell count after discontinuation of antiretroviral therapy) thanks to effectively targeting residual virus replication and viral reservoirs. In order to do so, the planned novel strategy is to successfully combine immune-based therapies, including therapeutic vaccines and broadly neutralizing antibodies with latency reversing agents, in a proof-of-concept phase IIa clinical trial. HIVACAR project will lead to a reduction of the actual c...
Any information missing or wrong?Report an Issue